peptides&elephants receives ProFIT funding for MHC Class I Peptide Pool launch

Dr. Oliver Kreuzer beside the ProFIT funding certificate

peptides&elephants has received funding through Brandenburg’s ProFIT Innovation Program, co-financed by the European Regional Development Fund (EFRE) and the State of Brandenburg.

The project “Market Launch: Establishment of a New Peptide Product Family – Introduction of Novel MHC Class I Peptide Pools” supports the development of a next-generation MHC Class I Peptide Pool product line. These peptide tools will advance immunological research by enabling more precise studies of T cell responses and antigen presentation.

With ProFIT support, peptides&elephants will:

  • Launch innovative MHC Class I Peptide Pools
  • Expand peptide synthesis and purification at the Hennigsdorf site
  • Strengthen collaborations within Brandenburg’s biotech ecosystem

This project bridges peptide chemistry and translational immunology — helping to accelerate discoveries in infectious disease and cancer research.

Pioneering Spirit & Precision

peptides&elephants is your trusted partner for high-quality research peptides and advancements in T-cell immunology. For 25 years, we have combined deep expertise in peptide chemistry with innovative engineering to drive progress in cancer and infectious disease research worldwide. Founded in 2001 by Dr. Oliver Kreuzer as a spin-off from the German Institute of Human Nutrition Potsdam and the Charité Berlin, our company stands for first-hand technological innovation. 

By developing our synthesis robots in-house, we created the market-leading, patented Ultrasonic Peptide Synthesis USPS® platform, capable of synthesizing 192 separate peptides in just eight hours. From routine catalog orders to complex custom syntheses, our dedicated team provides personalized service, absolute batch consistency, and maximum efficiency for projects of any scale.

Subscribe to newsletter
Privacy*
Fields marked with asterisks (*) are required.